Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Novartis Pharmaceuticals
Rapcabtagene autoleucel is a cell therapy of autologous T cells engineered to express a chimeric antigen receptor.
Summary written with AI from the sources listed at the end of this page.
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large B-cell LymphomaLarge B-cell LymphomaSmall Lymphocytic Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →